The kidney plays a critical role in metabolite excretion, fluid regulation, and homeostasis, yet remains highly vulnerable to structural and functional disorders. Kidney diseases represent a major global health burden, often progressing to chronic complications due to the limited efficacy and poor selectivity of conventional therapies, which are frequently associated with systemic toxicity. Accordingly, the development of targeted drug delivery systems is essential to improve therapeutic outcomes. In this study, advanced quatsomes were developed as a kidney-targeted nanosystem to enhance the delivery of curcumin, a natural polyphenolic compound with potent antioxidant and nephroprotective properties. The system was composed of di-dodecyl-dimethyl-ammonium bromide (DDAB), cholesterol, limonene, hyaluronic acid (HA) and surfactants, and was fabricated using the ethanol injection method. A 23 factorial design was employed to optimize formulation variables, including DDAB:cholesterol ratio, limonene:drug ratio, and surfactant concentration. The optimized formulation (desirability = 0.950) exhibited high entrapment efficiency (87.80%), nanosized vesicles (120.55 nm), and a positive surface charge (+38.30 mV). Transmission electron microscopy confirmed spherical morphology, while in-vitro release studies demonstrated a biphasic profile. The formulation also showed good physicochemical stability and enhanced antioxidant activity. Mechanistically, passive targeting via nanoscale size and cationic charge facilitated interaction with the glomerular filtration barrier and mesangial uptake, while limonene improved vesicle deformability. HA functionalization further enabled CD44-mediated active targeting. In vivo, the optimized system significantly reduced serum creatinine and blood urea nitrogen levels in a cisplatin-induced nephrotoxicity model, with histological evidence of renal protection. Overall, the developed quatsomes demonstrate promising potential as an efficient renal-targeted nanocarrier.
These findings establish the nasal NLU formulation as a promising therapeutic platform to mitigate doxorubicin-induced cardiotoxicity and exhibit superior cardioprotective and antioxidant performance over the oral NFP.
H. Farouk, F. A. Abo El-Ela, Fahad H. Baali et al.· Journal of drug targeting (P...· 0 citations
The promise of hyaluronic acid-based polymeric nanoparticles as a powerful nanoplatform to improve curcumin delivery and maximize anticancer effects by modulating key intracellular signaling pathways is highlighted, offering a strategy to overcome its biopharmaceutical limitations.
Xinyao Du, Song Xu, Fei Xu et al.· BioNanoScience· 0 citations
HA@Cel/NPs offer a versatile, dual-route platform that bridges inflammation management and cancer immunotherapy, distinguishing itself from single-mechanism or single-disease nanocarriers.
Jinfeng Shi, Xue-Qian Zhang, Lin-Xing Yang et al.· International Journal of Nan...· 0 citations
Tumor-targeting efficiency and safety assessment showed insignificant changes in the systemic biomarker levels and hemocompatibility, and the developed pPBA nanoconstructs offer a novel framework for an effective and targeted delivery of therapeutics.
Sneha K Thonnamkuzhi, Sayali Dighe, Vivek Yadav et al.· Nanomedicine: Nanotechnology...· 0 citations
This review focuses on a targeted introduction of the herbal nanocarrier-based treatment approach for liver diseases and the correlation between the various properties of the nanocarrier and the enhancement effect of the plant-derived compounds’ delivery in the liver.
Utpal Bhui, S. Sen, Sudipta Roy et al.· Journal of Medicinal Natural...· 0 citations
C cumulative preclinical evidence validates CUR’s therapeutic potential as a natural anti-fibrotic agent in experimental settings, and shows great prospects for developing anti-fibrotic functional foods and clinical therapeutics, yet high-quality human clinical trials are still urgently needed to confirm its real-world...
Ling-Ji Deng, Xiao-Qin Liu, Hao-Yue Feng et al.· Drug Design, Development and...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.